Michael P. Dube is CAO & VP at Intellia Therapeutics, Inc. (NTLA). They have made 7 open-market trades across 1 company since 2024, most recently 2026-10-02.
CIK 0002019493
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 7 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| NTLA | 65,022 | $800K |
Shares reported on the most recent Form 4, priced at the 2026-10-06 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| NTLA | SELL | 2026-10-02 | 2026-10-06 | $12.43 | $23K | -5.8% | — | — |
| NTLA | SELL | 2026-07-01 | 2026-07-06 | $16.78 | $44K | -33.8% | -38.8% | -28.7% |
| NTLA | SELL | 2026-01-05 | 2026-01-07 | $9.21 | $28K | +19.7% | +14.6% | +26.5% |
| NTLA | SELL | 2025-10-01 | 2025-10-03 | $17.38 | $33K | +23.1% | -37.9% | -56.3% |
| NTLA | SELL | 2025-07-02 | 2025-07-03 | $9.95 | $25K | +12.3% | +13.8% | +76.2% |
| NTLA | SELL | 2025-01-03 | 2025-01-07 | $12.18 | $17K | -17.4% | -15.9% | -45.7% |
| NTLA | SELL | 2024-10-02 | 2024-10-04 | $19.01 | $38K | +14.6% | -15.7% | -32.0% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.